Skip to search formSkip to main contentSkip to account menu

PM 00104

Known as: PM-00104, PM00104 
A synthetic alkaloid compound, related to natural alkaloid compounds, found in molluscs (jorumycin) and sponges (renieramycins), with potential… 
National Institutes of Health

Related topics

Related topics

4 relations
DNANCIt Antineoplastic Agent Terminology

Broader (1)

Tetrahydroisoquinolines

Narrower (1)

Zalypsis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
Despite improvements in the prognosis of multiple myeloma (MM) associated with the recent introduction of immunomodulatory drugs… 
Review
2014
Review
2014
PM00104 (Zalypsis®): A Marine Derived Alkylating Agent
PM00104 (Zalypsis®) is a synthethic tetrahydroisoquinolone alkaloid, which is structurally similar to many marine organisms. The… 
Highly Cited
2013
Highly Cited
2013
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
This study: (i) investigated the in vitro cytotoxicity and mode of action of lurbinectedin (PM01183) and Zalypsis® (PM00104… 
2013
2013
Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer
This open-label, two-arm, phase II clinical trial evaluated the antitumor activity and safety profile of PM00104 (Zalypsis… 
2013
2013
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
SummaryPM00104 (Zalypsis®) is a new synthetic alkaloid with potent cytotoxic activity against tumor cell lines. This phase I… 
2012
2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
Background:PM00104 binds guanines at DNA minor grooves, impacting DNA replication and transcription. A phase I study was… 
2011
2011
Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients
ObjectiveThe aim of this study was to characterize the population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients… 
2009
2009
Zalypsis (PM00104) is a potent inducer of γ-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition
Zalypsis (PM00104) is a novel tetrahydroisoquinoline alkaloid related to trabectedin [ecteinascidin 743 (Et743)]. Et743 and… 
2009
2009
Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
PurposeET-743 (Yondelis®, trabectedin) and PM00104 (Zalypsis®) are marine derived compounds which demonstrate anti-tumor activity… 
2005
2005
The novel compound PM00104 exhibits significant in vivo activity against breast tumors. PM00104 exhibits significant in vivo activity against breast tumors
623 In vivo tumor profiling of compound PM00104 demonstrated strong antitumor activity in breast, gastric, prostate, and renal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)